NasdaqGM:BSTC

Stock Analysis Report

Executive Summary

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.

Share Price & News

How has BioSpecifics Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.9%

BSTC

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-21.9%

BSTC

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: BSTC underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: BSTC underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

BSTCIndustryMarket
7 Day-2.9%1.6%0.4%
30 Day-16.5%-2.4%-1.2%
90 Day-19.9%-1.5%-0.4%
1 Year-21.9%-21.9%-6.9%-7.7%9.3%6.9%
3 Year7.4%7.4%14.7%10.7%45.8%36.4%
5 Year20.9%20.9%-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is BioSpecifics Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioSpecifics Technologies undervalued compared to its fair value and its price relative to the market?

7.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: BSTC ($48.78) is trading below our estimate of fair value ($52.83)

Significantly Undervalued: BSTC is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: BSTC is good value based on its PE Ratio (16.1x) compared to the Biotechs industry average (16.9x).

PE vs Market: BSTC is good value based on its PE Ratio (16.1x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BSTC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BSTC is overvalued based on its PB Ratio (3.2x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is BioSpecifics Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

16.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSTC's forecast earnings growth (16.1% per year) is above the savings rate (2.7%).

Earnings vs Market: BSTC's earnings (16.1% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: BSTC's earnings are forecast to grow, but not significantly.

Revenue vs Market: BSTC's revenue (12.8% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: BSTC's revenue (12.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if BSTC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioSpecifics Technologies performed over the past 5 years?

26.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BSTC's earnings have grown significantly by 26.6% per year over the past 5 years.

Accelerating Growth: BSTC's earnings growth over the past year (55.6%) exceeds its 5-year average (26.6% per year).

Earnings vs Industry: BSTC earnings growth over the past year (55.6%) underperformed the Biotechs industry 78.4%.


Return on Equity

High ROE: BSTC's Return on Equity (20%) is considered high.


Return on Assets

ROA vs Industry: BSTC has a higher Return on Assets than the Biotechs industry average last year.


Return on Capital Employed

ROCE Improving: BSTC's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is BioSpecifics Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: BSTC's short term assets ($103.0M) exceeds its short term liabilities ($1.6M)

Long Term Liabilities: BSTC has no long term liabilities


Debt to Equity History and Analysis

Debt Level: BSTC is debt free.

Reducing Debt: BSTC has not had any debt for past 5 years.

Debt Coverage: BSTC has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BSTC has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: BSTC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BSTC's debt is covered by short term assets.


Next Steps

Dividend

What is BioSpecifics Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BSTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BSTC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BSTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BSTC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BSTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of BioSpecifics Technologies's salary, the management and board of directors tenure and is there insider trading?

12.3yrs

Average board tenure


CEO

J. Buchi (64yo)

0yrs

Tenure

0

Mr. J. Kevin Buchi serves as Director of Dicerna Pharmaceuticals, Inc. since August 16, 2018 and has been its Chairman since January 24, 2019. Mr. Buchi has been Chief Executive Officer of BioSpecifics Tec ...


Board Age and Tenure

12.3yrs

Average Tenure

78yo

Average Age

Experienced Board: BSTC's board of directors are seasoned and experienced ( 12.3 years average tenure).


Insider Trading

Insider Buying: BSTC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$551,67711 Sep 19
Toby Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$55.23
SellUS$26,87410 Jun 19
Jennifer Chao
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares459
Max PriceUS$58.55
SellUS$315,54306 Jun 19
Jennifer Chao
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,511
Max PriceUS$58.01
SellUS$352,80005 Jun 19
Patrick Caldwell
EntityIndividual
Role
Chief Financial Officer
Interim Principal Financial Officer
Shares6,000
Max PriceUS$58.80
SellUS$201,23203 Jun 19
Jennifer Chao
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,313
Max PriceUS$60.74
SellUS$476,50228 May 19
Mark Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares7,800
Max PriceUS$61.09
SellUS$76,44023 May 19
Mark Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,200
Max PriceUS$63.70
SellUS$352,35322 May 19
Toby Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,500
Max PriceUS$64.67
SellUS$384,23622 May 19
Mark Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares6,000
Max PriceUS$64.04
SellUS$329,15017 May 19
Paul Gitman
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$65.83

Ownership Breakdown


Management Team

  • J. Buchi (64yo)

    Chief Executive Officer

    • Tenure: 0yrs
  • Patrick Caldwell (57yo)

    Interim Principal Financial Officer

    • Tenure: 0.5yrs
  • Ronald Law (66yo)

    Senior Vice President of Business Development

    • Tenure: 0.9yrs
  • Carl Valenstein

    Corporate Secretary

    • Tenure: 0yrs

Board Members

  • Paul Gitman (78yo)

    Independent Director

    • Tenure: 29.8yrs
    • Compensation: US$45.00k
  • Michael Schamroth (79yo)

    Independent Director

    • Tenure: 15.4yrs
    • Compensation: US$45.00k
  • Jenn Chao (49yo)

    Independent Director

    • Tenure: 4.5yrs
    • Compensation: US$340.15k
  • Toby Wegman (84yo)

    Director

    • Tenure: 12.3yrs
    • Compensation: US$22.00k
  • Mark Wegman (69yo)

    Director

    • Tenure: 12.3yrs
    • Compensation: US$50.00k

Company Information

BioSpecifics Technologies Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioSpecifics Technologies Corp.
  • Ticker: BSTC
  • Exchange: NasdaqGM
  • Founded: 1957
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$357.574m
  • Shares outstanding: 7.33m
  • Website: https://www.biospecifics.com

Number of Employees


Location

  • BioSpecifics Technologies Corp.
  • 35 Wilbur Street
  • Lynbrook
  • New York
  • 11563
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BSTCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 1991
1B3BST (Boerse-Stuttgart)YesCommon StockDEEURNov 1991

Biography

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and international ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 23:33
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.